Skip to content

Hemp Seed Awareness

Hemp Seed Awareness

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04841954
Acronym
ARCHANGE
Enrollment
600
Registered
2021-04-12
Start date
2021-06-01
Completion date
2025-05-31
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

Hemp is a plant of the Cannabaceae family. Cannabis sativa, derived from female flowers, is the first illicit substance used by adolescents and is a major public health problem. Its psycho-active effects come from tetrahydrocannabinol (THC). Unlike recreational cannabis, industrial hemp derived from cannabis sativa has a high level of cannabidiol (CBD) but a negligible level of tetrahydrocannabinol. Its seeds are now consumed in various forms and generate increasing interest. Seeds have many nutritional benefits. It seems important to take an interest in hemp, given the recent expansion of medical cannabis and the increasing use of cannabis for recreational purposes. It is incriminated in various allergies (contact dermatitis, asthma, rhinoconjunctivitis) but also in the occurrence of anaphylaxis to certain foods by cross-allergy in atopic subjects, in association with an Lipid-Transfer Proteins (LTP protein), present in the flower of Cannabis sativa. Unlike the allergy to recreational cannabis, the allergenicity of hemp seeds is little studied. Hemp seed can cause severe anaphylactic reactions. In all reported cases, the prick-tests were positive for the seeds. Often, patients had never been in contact with hemp seeds but had already been exposed to cannabis by respiratory or manual routes. The investigators hypothesize that sensitization by the skin or respiratory route (cannabis smokers, passive exposure to cannabis, workers exposed to hemp, etc.) could lead to the development of a food allergy to hemp seed.

Interventions

DIAGNOSTIC_TESThemp prick-test

hemp seed and flower prick-test

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Major patient * Patient referred to the Allergology Unit of the Hospital of Angers, in consultation or in Hospitalization - for conducting prick-tests * Patient affiliated or beneficiary of a social security scheme * Patient with informed consent

Exclusion criteria

* Pregnant women, parturients * Persons deprived of liberty by administrative or judicial decision * Persons receiving psychiatric care under duress * Adults under legal protection measure * People out of state to express consent * people not able to understand French language * Patients whose skin reactivity prevents interpretation of tests (patients who cannot interrupt anti-histamines or have severe eczema)

Design outcomes

Primary

MeasureTime frameDescription
Positive prick-testDay 1To assess the prevalence of hemp seed sensitization in the allergy consulting population

Secondary

MeasureTime frameDescription
history of hemp useDay 1To study the association between sensitization to hemp seed and patient characteristics

Countries

France

Contacts

Primary ContactMartine MORISSET
martine.morisset@chu-angers.fr0241353637
Backup ContactDRCI Promotion Interne
DRCI-Promotion-Interne@chu-angers.fr0241353637

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026